U.S. markets closed
  • S&P 500

    3,380.80
    +17.80 (+0.53%)
     
  • Dow 30

    27,816.90
    +35.20 (+0.13%)
     
  • Nasdaq

    11,326.51
    +159.00 (+1.42%)
     
  • Russell 2000

    1,525.77
    +18.08 (+1.20%)
     
  • Crude Oil

    38.68
    -1.54 (-3.83%)
     
  • Gold

    1,911.30
    +15.80 (+0.83%)
     
  • Silver

    23.93
    +0.44 (+1.86%)
     
  • EUR/USD

    1.1752
    +0.0026 (+0.22%)
     
  • 10-Yr Bond

    0.6770
    0.0000 (0.00%)
     
  • GBP/USD

    1.2891
    -0.0030 (-0.23%)
     
  • USD/JPY

    105.5420
    +0.1120 (+0.11%)
     
  • BTC-USD

    10,614.79
    -181.25 (-1.68%)
     
  • CMC Crypto 200

    218.68
    -5.02 (-2.24%)
     
  • FTSE 100

    5,879.45
    +13.35 (+0.23%)
     
  • Nikkei 225

    23,185.12
    0.00 (0.00%)
     

What Is The Ownership Structure Like For Kezar Life Sciences, Inc. (NASDAQ:KZR)?

Simply Wall St

Every investor in Kezar Life Sciences, Inc. (NASDAQ:KZR) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

Kezar Life Sciences is a smaller company with a market capitalization of US$219m, so it may still be flying under the radar of many institutional investors. Taking a look at our data on the ownership groups (below), it's seems that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Kezar Life Sciences.

View our latest analysis for Kezar Life Sciences

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Kezar Life Sciences?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Kezar Life Sciences already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Kezar Life Sciences's earnings history, below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Kezar Life Sciences. Equal Talent Investments Ltd is currently the company's largest shareholder with 14% of shares outstanding. For context, the second largest shareholder holds about 14% of the shares outstanding, followed by an ownership of 13% by the third-largest shareholder. Furthermore, CEO John Fowler is the owner of 0.0084212 of the company's shares.

Our research also brought to light the fact that roughly 54% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Kezar Life Sciences

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board; and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board, themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

It seems insiders own a significant proportion of Kezar Life Sciences, Inc.. Insiders own US$37m worth of shares in the US$219m company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

General Public Ownership

The general public holds a 13% stake in KZR. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With a stake of 13%, private equity firms could influence the KZR board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Private Company Ownership

Our data indicates that Private Companies hold 14%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Kezar Life Sciences better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Kezar Life Sciences (at least 2 which are a bit unpleasant) , and understanding them should be part of your investment process.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.